​​​​​About the CAVD

A preventative HIV vaccine has the potential to control the global AIDS epidemic and avert the suffering of millions of people. Roughly 6,000 people become infected with HIV each day, for a total of approximately 2.7 million new infections per year. Worldwide, an estimated 33 million people are living with H​IV/AIDS, with 22 million of those individuals living in sub-Saharan Africa.

Despite over 20 years of HIV vaccine research, the scientific challenges have so far blocked the development of a preventative vaccine. As a result, HIV vaccine scientists, advocates, and funders are searching for innovative approaches to vaccine research and development. One such approach emphasizes collaboration and concentration of effort by a worldwide network of researchers dedicated to accelerating the pace of HIV vaccine research.

The CAVD provides funding for a range of innovative strategies aimed at designing an effective HIV vaccine. The program is designed to foster collaboration among researchers to speed up the communication of results and the sharing of ideas. In addition to focusing on fundamental HIV research, the funded projects emphasize translational research, bridging the gap between basic discovery and product development.

The CAVD approach is based on the principle that HIV vaccine development will progress most rapidly and has the highest chance of success if the individual initiatives are complemented by a collaborative effort. Small teams of independent researchers conduct much of today’s scientific work, and their findings form the basis for numerous innovations. However, independent efforts have thus far failed to produce a preventative vaccine, and a consensus has emerged among researchers, advocates, and funders that large-scale projects featuring collaboration and concentration of efforts could accelerate the pace of HIV vaccine research.

The CAVD fosters a spirit of open communication and sharing not only of data but also of methods, reagents, and specimens in a collegial network of research consortia and central service facilities.

The program seeks a balance between productive competition and collaboration. The grantees use standardized tools and common preclinical and clinical platforms that permit the evaluation and sharing of results, while preserving the independent research crucial to innovation.

See About the CAVD Structure…

Former CAVD Grants​​
​

Grant    Grant Award Year    Shattock: Novel Antigens for Mucosal Protection 2005 ​Ho: Enhancing Innate Immune Activation 2006 Greenberg: Mouse Immunology Laboratory 2006 Haynes: Broad Neutralizing Antibody Consortium 2006 Lehner Vaccine Discovery Consortium 2006 Letvin: rAdenoviral & rMycobacterial Vector Immunogens 2006 McElrath: Innate to Adaptive Immunity 2006 Parks: Replicating Viral Vaccine Vectors 2006 Patterson: CD8 Broadening Strategies 2006 Plummer, Grand Challenges in Global Health 2006 ​Reinherz: HIV clade C MPER immunogens eliciting 10E8-like speci cities 2006 Stamatatos: Novel HIV Immunogen Vaccines 2006 Weiss: Protection by Neutralizing Antibodies 2006 Zolla-Pazner: Epitope-Scaffold Immunogens 2006 ​Gallo: Systemic, Mucosal & Passive Immunity 2007 Walker: HIV Control & Immunogen Design 2007 Haynes: Centralized Envelope Phase I Study 2009 Ho: Ibalizumab for HIV Prevention 2009 Pantaleo: Poxvirus-Based Vaccine Development 2009 von Briesen: HIV Specimen Cryorepository 2009 Wilson: Vector-Mediated Passive Immunization 2009 ​Frank: Studies to Maximize Immunogenicity 2011 ​Picker: Development of Attenuated CMV Vectors for an HIV/AIDS Vaccine 2011 Ackerman/Alter: Leve​raging Antibody Effector Function 2011 Barouch: Replicating Adenovirus Vectors 2011 Haynes: B-Cell Lineage Envelope Design 2011 Hope: Antibody-Mucus Interactions 2011 ​Hu: Unmasking Conserved Epitopes 2011 Lewis: Ab Specificity & Fc-Mediated Protection 2011 Lu: Creating Novel Envelope Immunogens with Unique Sugar Coats for HIV Vaccine Development 2011 Mascola: BNAbs for Passive Immunization 2011 ​Nussenzweig: Isolation of Human Monoclonal Antibodies for HIV Prevention​ 2011 ​Parks: HIV Vaccine Clinical Candidates based on Replication-Competent Viral Vectors that Preferentially Replicate in Lymphoid Tissues 2011 Schmitz/Santra: Second Generation rBCG Immunogens 2011 ​​Haynes: Role of IgA in HIV-1 Protection 2012 ​​Ho: Engineered Bispecific bNAbs for Prevention 2012 ​Bjorkman: Improving Potency and Breadth of Natural bNAbs 2012 Barouch: Novel Vector/Protein Vaccines 2012 ​Pantaleo: RepliVax Vaccine Platform 2012 Überla: Antibodies without HIV T helper cells 2012 Walker: bNAbs after Infection and Immunization 2012 Alter: A Genetic Approach to Optimizing the Antigenicity of HIV-1 Envelope 2013 Kay: Identifying rAAV Vectors with Enhanced Muscle Transduction via Capsid Evolution 2013 Kublin: HIV Vaccine Trials Site Development for the P5 Program 2013 ​​​McElrath: Mucosal Immunology Group 2013 Shattock: DNA Vaccination for HIV Immunogen Discovery 2013 Silvestri: Independent Confirmation of Inactivated AT-2 Treated SIV mac239 and Lactobacillus 2013 ​Nolan: Technology Development for HIV Reservoir Characterization 2014 ​Pantaleo: Generation/Isolation of Novel bNAbs from Lymph Node B cells 2014 ​Ruprecht: Confirming the Efficacy of Virosomes Targeting gp41 in Indian Rhesus Macaques 2014 Alter: Defining Signatures of Antibody Responses that Correlate with Protection to Develop Down-Selection Criteria to Guide Vaccine Candidate Selection 2014 Baker: Testing the Nearest Neighbor Approach to Active Vaccination for HIV-1 bNAbs 2014 Barouch: Therapeutic Efficacy of Potent Broadly Neutralizing mAbs for HIV-1 Eradication 2014 ​Deeks: Experimental medicine trial to assess the impact of interferon-alpha inhibition on immune function and viral persistence in HIV disease 2014 Kublin: HVTN:100 2014 McMichael: HLA-E restricted CD8 responses induced by CMV vaccines​ 2014 Nolan: Technology Development for HIV Reservoir Characterization 2014 Pantaleo: Generation/Isolation of Novel bNAbs from Lymph Node B cells 2014 Reinherz: HIV clade C MPER immunogens eliciting 10E8-like speci cities 2014 ​Farzan: Preventing HIV-1 transmission with eCD4-Ig 2015 Masopust: Vaccination to prevent HIV Infection 2015 Nussenzweig: Development of optimized broadly neutralizing antibodies for HIV-1 prevention​ 2015 Ward: Establishment of an Analytics Network to Support Qualified/Validated Assays Required for Characterization of HIV Env Immunogens 2015 Kay: Comparative NHP Study to Test New Capside Against AAV1 2016 Parks: HIV Vaccine Clinical Candidates based on Replication-Competent Viral Vectors that Preferentially Replicate in Lymphoid Tissues 2016 Parks: Live Attenuated VSV-HIV-Env Vaccine Candidate for Evaluation in a Clinical Trial (I) 2016 Parks: Live Attenuated VSV-HIV-Env Vaccine Candidate for Evaluation in a Clinical Trial (II) 2016 Shaw: Novel SHIV Design to Elicit Broadly Neutralizing Antibodies and Guide Iterative Vaccine Development 2016 Walker: Implications for vaccine design from T and B cell mechanisms of HIV control 2016 Alt: Physiologically Relevant and Rapidly Generated HIV-1 Vaccine Mouse Models 2017 Barouch: Epitope-Modified Env Trimers for Induction of Heterologous Tier 2 NAbs 2017 Batista: Accelerating Vaccine Design through Interrogation of Physiologically Relevant Mouse Models 2018 Crotty: Improving the identification of epitope-specific precursor naive B cells in the human B cell repertoire 2018 Kim: AVANTI: An Alliance for Vaccine Access, New Technology, and Innovation 2019

Follow

javascript: SP.SOD.executeFunc('followingcommon.js', 'FollowDoc', function() { FollowDoc('{ListId}', {ItemId}); });

0x0

0x0

ContentType

0x01

1100

Run now

/about/_layouts/images/HarePointScheduler/run_now.png

javascript: void(HarePointScheduler.ContextClick('Run_now', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x0037D1A977040C4133BE7822D7AF2D22DD

40

Enable

/about/_layouts/images/HarePointScheduler/enable.png

javascript: void(HarePointScheduler.ContextClick('Enable', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x0037D1A977040C4133BE7822D7AF2D22DD00A36433F5D1584B3D8625A0D95311AB7C

60

Disable

/about/_layouts/images/HarePointScheduler/disable.png

javascript: void(HarePointScheduler.ContextClick('Disable', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x0037D1A977040C4133BE7822D7AF2D22DD0030C14E73870D4F3D8F23EF41728D8A67

60

Stop Instances

/about/_layouts/images/HarePointScheduler/stop.png

javascript: void(HarePointScheduler.ContextClick('Stop_instances', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x0037D1A977040C4133BE7822D7AF2D22DD

50

Stop Instance

/about/_layouts/images/HarePointScheduler/stop.png

javascript: void(HarePointScheduler.ContextClick('Stop_instance', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x002CBCC5F171F54C4B8FB601813349C162

50

Compliance Details

javascript:if (typeof CalloutManager !== 'undefined' && Boolean(CalloutManager) && Boolean(CalloutManager.closeAll)) CalloutManager.closeAll(); commonShowModalDialog('{SiteUrl}'+ '/_layouts/15/itemexpiration.aspx' +'?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/hold.aspx' +'?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/Reporting.aspx' +'?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/expirationconfig.aspx' +'?ID={ItemId}&List={ListId}'); return false;}}, null);

0x0

0x1

ContentType

0x01

898

Document Set Version History

/_layouts/15/images/versions.gif?rev=40

javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}'+ '/_layouts/15/DocSetVersions.aspx' + '?List={ListId}&ID={ItemId}')

0x0

0x0

ContentType

0x0120D520

330

Send To other location

/_layouts/15/images/sendOtherLoc.gif?rev=40

javascript:GoToPage('{SiteUrl}' + '/_layouts/15/docsetsend.aspx' + '?List={ListId}&ID={ItemId}')

0x0

0x0

ContentType

0x0120D520

350

​